Address: 823 Jays Drive
Lansdale, PA 19446,United States of America
Tel:
Web: http://www.jdptherapeutics.com/default.aspx
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life-threatening diseases with significant unmet medical needs, primarily for use in acute care in a hospital setting.
Small Molecule Therapeutics
Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no fewer than four…
As Breast Cancer Awareness Month 2024 draws to a close, PhRMA’s Elizabeth Carpenter lays out the massive progress made in breast cancer treatment outcomes over the past half-century. However, Carpenter…
Pfizer CEO Albert Bourla’s ‘annus horribilis’ shows no sign of abating. From being feted as the industry darling of the COVID-19 period, Pfizer management is now being accused of USD…
Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment…
Monica Weldon, a seasoned rare disease patient advocate in the US, now serves as the lead strategic analyst for the life science industry base policy at Leidos, a technology solutions…
In the October 2024 edition of DIA’s Global Forum magazine, Global Forum founding Editor-in-Chief and former DIA board member Andrzej Czarnecki of Eli Lilly and Company shares his reflections on…
In a country characterised by its racial and ethnic diversity, but where less than 5 percent of clinical trial data includes racial and ethnic factors, clinical trial diversity has become…
Troubled gene sequencing firm Illumina has announced a new strategy to accelerate growth. Under the leadership of CEO Jacob Thaysen, Illumina hopes to turn the page on a recent history…
Contract research organisations (CROs) have proven to be increasingly vital partners for the global biopharmaceutical industry guaranteeing efficient and compliant clinical trials that help to advance their candidates towards regulatory…
Against the backdrop of a global push to make healthcare more accessible and affordable, ISPOR CEO and executive director Rob Abbott introduces the organisation’s 2030 strategy, focused on achieving health…
AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA)…
DIA’s Sorcha McCrohan, contributing to the the August 2024 edition of DIA’s Global Forum magazine, reviews insights from the town hall meetings that brought together regulators from around the world…
See our Cookie Privacy Policy Here
